Atara Biotherapeutics, Inc

ATRANASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
9.81 USD
↗ 0.37 (3.87%)🟢LIVE (AS OF 02:11 PM EDT)
🟢Market: OPEN

Atara Biotherapeutics, Inc (ATRA) trades at $9.81 per share. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, exceptional Return on Equity (45.1%), a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Sep 15, 2026.

Open?$9.50
High?$9.89
Low?$9.30
Prev. Close?$9.44
Volume?33.9K
Avg. Volume?49.1K
VWAP?$9.63
Rel. Volume?0.69x
Bid / Ask
Bid?$8.14 × 100
Ask?$11.33 × 100
Spread?$3.19
Midpoint?$9.74
Valuation & Ratios
Market Cap?94.8M
Shares Out?10.0M
Float?2.6M
Float %?29.0%
P/E Ratio?N/A
P/B Ratio?-2.56
EPS?-$1.66
Dividend?0.00%
Ex-Dividend?N/A
RelatedORIC
News
Profile
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Immunology & Autoimmune
Employees
10
Market Cap
94.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.atarabio.com
Listed
2014-10-16
Address
1280 RANCHO CONEJO BLVD
THOUSAND OAKS, CA 91320
Phone: 805-623-4211
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
0
Momentum?
2
Short Sent.?
44
Piotroski F-Score?1/9Weak
Altman Z-Score?-135.81Distress
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?16.35%High
Short Interest?427.4K
Days to Cover?11.1
Free Float2.6M
Avg Daily Volume38.6K
Settlement Date2026-08-31
Financial Health
Current Ratio?1.98Adequate
Quick Ratio?1.98Adequate
Cash Ratio?0.47Low
Debt/Equity?-0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
-2.56CHEAP▾
P/S?
S&P
3
15.30HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.5CHEAP▾
EV/Sales?
S&P
3
14.78HIGH▾
Returns & Efficiency
ROE?
S&P
90
45.1%STRONG▾
ROA?
S&P
3
-79.4%WEAK▾
Cash Flow & Enterprise
FCF?$-21895000
Enterprise Value?$91.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist